Cadrenal Therapeutics, Inc. 8-K

What Happened
Cadrenal Therapeutics (CVKD) filed an 8-K on June 29, 2026 announcing that the Board appointed John P. Sharp as Interim Chief Financial Officer effective June 25, 2026 and that director Steven Zelenkofske notified the company he will resign effective June 30, 2026. The company is conducting a search for a permanent CFO. The filing also describes a Board realignment completed June 29, 2026 that moved Dr. Glynn Wilson into a Class III director role and reappointed him to the Audit and Nominating & Corporate Governance Committees, and added him to the Compensation Committee.

Key Details

• John P. Sharp (age 61), Senior Director at Lohman & Associates and an experienced biopharma finance executive, was appointed Interim CFO effective June 25, 2026; the company is searching for a permanent CFO.
• Mr. Sharp’s services are provided under Statement of Work No. 5 pursuant to a Master Services Agreement (dated Aug. 21, 2024) with Lohman & Associates; billing is $455 per hour for up to 24 hours/week.
• Director Steven Zelenkofske resigned effective June 30, 2026 (not due to any disagreement with the company); the Board realigned classes and moved Dr. Glynn Wilson to Class III on June 29, 2026.
• Non-employee directors receive a $35,000 annual cash fee for fiscal 2026; directors may also receive equity awards.

Why It Matters
For investors, the appointment of an experienced interim CFO provides near-term financial leadership and continuity while the company searches for a permanent CFO. The use of Lohman & Associates at a disclosed hourly rate highlights the outsourced/consulting nature and cost structure of the interim arrangement. The board resignation and subsequent realignment affect governance and committee composition—important for oversight of finance, audit, and executive compensation—while the filing notes the resignation was not due to disagreement with company operations. The 8-K includes the underlying service agreements as exhibits for further detail.